Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention AI-powered digital twins, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Lawrence Berkeley National Laboratory (LBNL)
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention AI-powered digital twins, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. The 6 average consequence score is above the beat benchmark of 5.7 in the same window. We currently track 1 Biotech story that mention Lawrence Berkeley National Laboratory (LBNL), all published on August 1, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Lawrence Berkeley National Laboratory (LBNL). Shared-story counts are live from our verified record — not editorial picks.
eXoZymes lands a high-profile DOE grant to develop AI digital twins for cell-free enzyme manufacturing. The 9-month collaboration with Lawrence Berkeley Lab could slash process development timelines and unlock faster routes for nutraceuticals and novel therapeutics.
Lawrence Berkeley National Laboratory (LBNL) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.